
Travere Therapeutics, Inc. (($TVTX)) has held its Q3 earnings call. Read on for the main highlights of the call. Travere Therapeutics’ earnings call carried a strongly positive tone, led by
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| TVTX | Travere Therapeutics | 47.00 | 12.31 | 35.49% |
| Name | Price | % Change | |
|---|---|---|---|
| $47.00 | +35.49% |

Travere Therapeutics, Inc. (($TVTX)) has held its Q3 earnings call. Read on for the main highlights of the call. Travere Therapeutics’ earnings call carried a strongly positive tone, led by

JPMorgan lowered the firm’s price target on Travere Therapeutics (TVTX) to $86 from $90 and keeps an Overweight rating on the shares. Published first on TheFly – the ultimate source

Guggenheim analyst Vamil Divan lowered the firm’s price target on Travere Therapeutics (TVTX) to $78 from $89 and keeps a Buy rating on the shares. Published first on TheFly –

Canaccord analyst Edward Nash raised the firm’s price target on Travere Therapeutics (TVTX) to $72 from $70 and keeps a Buy rating on the shares. The firm updated its model

Travere Therapeutics, Inc. (TVTX) has disclosed a new risk, in the Corporate Activity and Growth category. Travere Therapeutics, Inc. faces heightened exposure to evolving U.S. and foreign regimes governing cross-border

Analyst Joseph Pantginis of H.C. Wainwright reiterated a Buy rating on Travere Therapeutics, retaining the price target of $67.00. Joseph Pantginis gave his Buy rating based on several factors, led

Travere Therapeutics (TVTX)’ Q3 Filspari patient starts declined 4% sequentially to 1,932, below expectations for growth, but revenue beat estimates by more than 10% even excluding one-offs, Cantor Fitzgerald tells

Reports Q3 revenue $224.6M, consensus $195.3M. “Strong execution across our business drove another quarter of significant growth, with FILSPARI net product sales of $200 million for the quarter as we

The F/m Emerald Life Sciences Innovation ETF (LFSC) ranks in the 12th percentile of Morningstar’s US Fund Health category, measured against 154 funds over the trailing one-year period as of

Travere Therapeutics, Inc. (TVTX) is scheduled to report 3rd quarter earnings on 11/02/2026, after the market closes. Regarding Q3 estimates, Wall Street analysts expect Travere Therapeutics, Inc. to post earnings
| Name | Analyst | Analyst Firm | Rating | Analyst Price Target | Action | Date |
|---|---|---|---|---|---|---|
| buy | Reiterated | Nov 16, 2026 | ||||
| buy | Reiterated | Nov 6, 2026 | ||||
| buy | Reiterated | Nov 4, 2026 | ||||
| hold | Reiterated | Nov 3, 2026 | ||||
| buy | Reiterated | Nov 3, 2026 | ||||
| buy | Reiterated | Nov 3, 2026 | ||||
| buy | Assigned | Nov 3, 2026 | ||||
| buy | Reiterated | Nov 3, 2026 | ||||
| buy | Reiterated | Nov 3, 2026 | ||||
| buy | Reiterated | Nov 3, 2026 |
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Feb 25, 2027TBA | $4.51B | $0.44 | $247.51M | 0.79 | -30.13 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.